Core Viewpoint - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1] Company Overview - Actuate's lead investigational drug, elraglusib, is a novel GSK-3β inhibitor that targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments [4] - Elraglusib may also enhance anti-tumor immunity by regulating multiple immune checkpoints and immune cell functions [4] Upcoming Events - Dan Schmitt, President & CEO of Actuate, will present at the Citizens Life Sciences Conference in Miami Beach, FL on March 10, 2026, at 8:25 a.m. ET [1] - A live webcast of the presentation will be available on Actuate's website, with a replay accessible for 30 days following the event [3]
Actuate Therapeutics to Present at The Citizens Life Sciences Conference